Melanoma

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

Retrieved on: 
Thursday, September 28, 2023
Research and development, University, Therapy, Stern Global Programs, Cancer, Bristol Myers Squibb, Eli Lilly, Development, Patient, School, Drug discovery, Tislelizumab, PD-1, Research, IND, Pfizer, Pharmaceutical industry, Melanoma, Novartis

AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer.

Key Points: 
  • AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer.
  • Dr. Voi will begin his new role on October 2, 2023.
  • Dr. Voi joins MTEM from Novartis, where he served as Vice President, Global Program Head, for the PD-1 antibody Tislelizumab since April 2021.
  • I look forward to this opportunity to exploit the full potential of these promising assets in the clinic,” said Dr. Maurizio Voi.

Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma

Retrieved on: 
Monday, September 25, 2023
Oncology, Health, Other Health, Managed Care, Research, Science, Biotechnology, Rigel, Melanoma, Incidence, Dermatology, ETF, Patient, Sentinel lymph node, Metastasis, Biology, ABCD syndrome, Neoplasm, Recurrence, Skin, Caregiver, Disease, Medical imaging, Medicine

“Castle is committed to our mission--improving health through innovative tests that guide patient care,” said Derek Maetzold, president and chief executive officer of Castle Biosciences and IMPACT Melanoma board member. “We are grateful for the opportunity to ring the closing bell in honor of patients with melanoma, their families and caregivers, and importantly, their clinicians, who we are privileged to partner with to help improve their care. At the end of the day, we are all working together to make an impact in people’s lives and perhaps provide something even more powerful than that … hope for the future.”

Key Points: 
  • “Castle is committed to our mission--improving health through innovative tests that guide patient care,” said Derek Maetzold, president and chief executive officer of Castle Biosciences and IMPACT Melanoma board member.
  • “We are grateful for the opportunity to ring the closing bell in honor of patients with melanoma, their families and caregivers, and importantly, their clinicians, who we are privileged to partner with to help improve their care.
  • IMPACT Melanoma is the nation’s leading non-profit dedicated to significantly reducing the incidence of melanoma in the United States and saving lives.
  • The live broadcast will begin at 3:50 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York.

SciBase initiates pilot with Bare Dermatology to advance skin cancer detection in Texas

Retrieved on: 
Monday, September 25, 2023
Skin, Bar code medication administration, Dermatology, SCIB, Melanoma, Patient, First Coast, FDA, Death, Medical imaging, Dallas–Fort Worth metroplex, Newsweek

STOCKHOLM, Sept. 25, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Bare Dermatology to pilot Nevisense in select locations in Texas.

Key Points: 
  • STOCKHOLM, Sept. 25, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Bare Dermatology to pilot Nevisense in select locations in Texas.
  • Bare Dermatology is a dermatology practice group in the Greater Dallas area, with five offices and a team of nationally renowned dermatologists.
  • The agreement will provide Bare Dermatology with Nevisense, the only FDA-approved test for early melanoma detection at point-of-care.
  • We are pleased to collaborate with Bare Dermatology as we expand across the US to address the early detection of melanoma needs", said Pia Renaudin, appointed Chief Executive Officer of SciBase.

Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer

Retrieved on: 
Thursday, September 21, 2023
KRAS, Antigen, DNA, Partnership, MD–PhD, Therapy, Blood, Doctor of Philosophy, Bacterial conjugation, Writing, MHC, Cancer, ML, Stanford University, Coronavirus Scientific Advisory Board, Microsoft, Addgene, Research, Monroe Dunaway Anderson, Harvard University, Haematopoietic system, Autoimmunity, TCR, Associate, MD Anderson Cancer Center, Chemistry, Genome, Patient, Machine learning, Melanoma, Engineering, Immune system, Autoimmune disease, Yale University, University, Physics, Biology, Entrepreneurship, Library, Synthetic biology, Prostate cancer, Pharmaceutical industry, Vaccine, Medical device, Replay, MD

This will be invaluable in helping Replay’s cell therapy product company Syena to advance novel TCR-NK therapies into the clinic.”

Key Points: 
  • This will be invaluable in helping Replay’s cell therapy product company Syena to advance novel TCR-NK therapies into the clinic.”
    “We’re thrilled to announce our first partnership with Replay and its product company Syena.
  • This partnership validates our approach of using synthesized human T cell repertoires to generate safe and effective libraries to discover antigen specific TCRs at scale,” said Elizabeth Wood, Ph.D., Founder & CEO, JURA Bio.
  • If the option is exercised, Replay and its cell therapy product company Syena will be responsible for global development and hold exclusive worldwide commercialization rights on all TCR-NK therapies resulting from the partnership.
  • Replay launched Syena, an oncology-focused product company, with The University of Texas MD Anderson Cancer Center in February 2023.

Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring

Retrieved on: 
Monday, September 18, 2023
Perk, NRAS, Workforce, FGFR, DNA, Pancreatic cancer, DUSP6, PRS, Class II, Class, DCR, Clinical trial, DC, DL 2, Trae tha Truth, First grade, MEK inhibitor, BRAF, Research, Itch, MEK, RNA, Lung cancer, Completeness, Binimetinib, Rash, ORR, Vomiting, Investment, Patient, SAN, Melanoma, ERK, Weakness, Nausea, ALT, Neoplasm, CDK4, FDA, FGFR2, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, SD, KNTE, Food, PR, Safety, Fatigue, RAF, Pharmaceutical industry, Cryptocurrency, Medical imaging, Vaccine

(Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based on a strategic review of its business.

Key Points: 
  • (Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based on a strategic review of its business.
  • Additionally, Kinnate will pause development of KIN-7136 and explore strategic alternatives for exarafenib monotherapy and KIN-3248, as part of the reprioritization plan.
  • We believe that reprioritizing our programs is the most effective approach to unlock the full promise of our innovative therapies.”
    Farzan added, “The reprioritization plan unfortunately impacts our workforce.
  • Kinnate will implement a corporate restructuring by reducing the Company’s workforce by approximately 70%.

JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer

Retrieved on: 
Thursday, September 21, 2023
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, KRAS, Antigen, Partnership, MD–PhD, Therapy, Blood, Doctor of Philosophy, Bacterial conjugation, MHC, Cancer, ML, Stanford University, Coronavirus Scientific Advisory Board, Microsoft, Addgene, Multimedia, Monroe Dunaway Anderson, Harvard University, Haematopoietic system, Autoimmunity, TCR, Associate, MD Anderson Cancer Center, Chemistry, Genome, Patient, Machine learning, Melanoma, University, Engineering, Immune system, Autoimmune disease, Yale University, Physics, Biology, Entrepreneurship, Library, Synthetic biology, Prostate cancer, Pharmaceutical industry, Management, Vaccine, Medical device, Replay, MD

JURA Bio , a biotechnology company developing immune-based therapeutics using machine learning and synthetic biology, announced today a research collaboration with Syena, a cell therapy product company and subsidiary of Replay, a genome writing company, to develop T cell receptor (TCR) based therapies.

Key Points: 
  • JURA Bio , a biotechnology company developing immune-based therapeutics using machine learning and synthetic biology, announced today a research collaboration with Syena, a cell therapy product company and subsidiary of Replay, a genome writing company, to develop T cell receptor (TCR) based therapies.
  • Photographer: Maki Suzuki
    “We’re thrilled to announce our first partnership with Replay and its product company Syena.
  • If the option is exercised, Replay and its cell therapy product company Syena will be responsible for global development and hold exclusive worldwide commercialization rights on all TCR-NK therapies resulting from the partnership.
  • Replay launched Syena, an oncology-focused product company, with The University of Texas MD Anderson Cancer Center in February 2023.

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer

Retrieved on: 
Friday, September 22, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Bristol Myers Squibb, IIA, OS, Lung cancer, Bladder cancer, Immunotherapy, BMY, Patient, Checkmate, Melanoma, EFS, NYSE, Nivolumab, Pharmaceutical industry, NSCLC

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC).
  • In a prespecified interim analysis, the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo showed a statistically significant and clinically meaningful improvement in EFS compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo.
  • The safety profile of this Opdivo-based regimen was consistent with previously reported studies in NSCLC.
  • To date, Opdivo and Opdivo-based combinations have shown improved efficacy in the neoadjuvant, adjuvant or perioperative treatment of four tumor types: lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma.

DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)

Retrieved on: 
Tuesday, September 19, 2023
Oncology, Health, Medical Devices, Health Technology, Health Insurance, Pharmaceutical, Biotechnology, DMT, Medicare, Dermatology, NPV, Blues, Melanoma, PLA, Blue, Health insurance, Highmark

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced agreements with Highmark Inc. (Highmark).

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced agreements with Highmark Inc. (Highmark).
  • The contracts, which are in addition to a favorable coverage policy, enhance access to the foundational assay of the DermTech Melanoma Test (DMT).
  • Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, West Virginia, Delaware and New York.
  • The Pigmented Lesion Assay (PLA), the foundational assay of the DMT, is an innovative, non-invasive way to rule out melanoma with a 99 percent negative predictive value (NPV).

The Melanoma Research Foundation to Host the 2023 LA Miles for Melanoma 5K!

Retrieved on: 
Thursday, September 21, 2023
Jonsson Comprehensive Cancer Center, Survivor, University, MRF, Dermatology, Australian Melanoma Research Foundation, Research, USC, Mile, Griffith Park, Novartis, Patient, Los, LOS, K, Vaccine, Nightclub, Pharmaceutical industry, L.A, Melanoma

LOS ANGELES, Sept. 21, 2023 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, care partners and survivors. This year we will be hosting our annual L.A. event on Saturday, October 7, 2023, at Griffith Park at 7:30am PT. The 5k walk/race will bring together the Los Angeles-area melanoma community with a goal of raising $70,000 in support of critical melanoma research.

Key Points: 
  • The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, care partners and survivors.
  • The 5k walk/race will bring together the Los Angeles-area melanoma community with a goal of raising $70,000 in support of critical melanoma research.
  • LOS ANGELES, Sept. 21, 2023 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, care partners and survivors.
  • Miles for Melanoma 5K event here by Wednesday, October 4th, 2023, at 11:59PM PT.

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

Retrieved on: 
Wednesday, September 20, 2023
Atezolizumab, Diabetes, Neoplasm, Doctor of Philosophy, ODA, National library, Patient, GC, Disease, Prostate cancer, Carcinoma, CD47, Hope, Research, ACHL, Lung cancer, NLM, Orphan drug, Death, Drug development, Diagnosis, Growth, Rare, FDA, Legislation, Civil service commission, ODD, Roche, Orphan Drug Act of 1983, PharmaMar, Cancer, NSCLC, Treatment of lung cancer, ES, Therapy, Stomach, ORR, European Commission, File, United States National Library of Medicine, MedImmune, Inc. v. Genentech, Inc., Clinical trial, Woman, Lung, Fast track (FDA), SCLC, American Cancer Society, Achilles, Melanoma, OTCQX, Orphan, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, RET, Food, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech, Pembrolizumab

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Key Points: 
  • Four decades after the Orphan Drug Act was passed, hundreds of 'orphan' drugs have been approved for use.
  • Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation.
  • Specifically, the report noted that 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases.
  • For companies looking to help those in the underserved rare-disease space, an Orphan Drug Designation is the ideal pathway to progress.